Erschienen in:
29.03.2018 | Breast Oncology
Delays in Adjuvant Chemotherapy Among Breast Cancer Patients: An Unintended Consequence of Breast Surgery?
verfasst von:
Debora de Melo Gagliato, MD, Mariana Chavez-MacGregor, MD, MSc
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 7/2018
Einloggen, um Zugang zu erhalten
Excerpt
Use of adjuvant chemotherapy plays a crucial role in improving the outcomes of breast cancer (BC) patients.
1,
2 In recent years, delays in administration of adjuvant chemotherapy have been associated with detrimental outcomes. The impact on outcomes is of significant magnitude, thus timeliness in chemotherapy administration has been proposed as a quality metric. Several studies have consistently identified that a delay in time to adjuvant chemotherapy (TTC) after definitive breast surgery was associated with adverse outcomes; patients receiving adjuvant chemotherapy 90 days after definitive breast surgery have worse overall and breast cancer-specific survival.
3,
4 Of particular relevance is that the detrimental impact of such delays seems to be greater among patients with more advanced stages and among those with highly proliferative tumors, particularly patients with triple-negative breast cancer (TNBC).
5 …
